Sulfuric acid sales are a pass-through causing sales to be lumpy, which is why ECVT reduced its sales outlook for 2022. However, adjusted EBITDA is now forecast towards the high end of the range
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.